Grifols

$15.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.37 (-2.30%) Today

$0.00 (0.00%) As of 11:00 PM UTC after-hours

Why Robinhood?

You can watch Grifols and buy or sell other stocks, options, and ETFs commission-free!

About GRFS

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain. The listed name for GRFS is Grifols, S.A. American Depositary Shares.

CEO

Raimon Grifols Roura

Employees

24,016

Headquarters

Barcelona, Catalonia

Founded

1940

Market Cap

15.48B

Price-Earnings Ratio

14.02

Dividend Yield

1.91

Average Volume

800.16K

High Today

$15.90

Low Today

$15.64

Open Price

$15.79

Volume

879.24K

52 Week High

$24.90

52 Week Low

$13.40

GRFS Earnings

$0.00

$0.15

$0.30

$0.45

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 9, Pre-Market